Please login to the form below

Not currently logged in
Email:
Password:

bladder cancer

This page shows the latest bladder cancer news and features for those working in and with pharma, biotech and healthcare.

Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

Roche’s Genetech nabs speedy review for Tecentriq in first-line breast cancer

Roche’ s Genetech nabs speedy review for Tecentriq in first-line breast cancer. ... Tecentriq is already approved in the US for certain types of bladder cancer and lung cancer, but has seen sales growth slow of late due to strong competition from other

Latest news

  • Ocrevus surge keeps Roche smiling in Q3 Ocrevus surge keeps Roche smiling in Q3

    However, the performance of Ocrevus and other drugs such as HER2 breast cancer therapy Perjeta (pertuzumab) and lung cancer therapy Alecensa (alectinib) – plus a strong showing in Asia-Pacific markets led ... The none-month figures show some headway in

  • A look ahead to key trial readouts at ESMO A look ahead to key trial readouts at ESMO

    It  will also have mid-stage data on the drug as a first-line monotherapy for non-muscle invasive bladder cancer (KEYNOTE-057). ... VEGF/FGF/PDGF inhibitor will give an update on lucitanib – also in HR+/HER2- breast cancer.

  • Imfinzi aces survival challenge in lung cancer Imfinzi aces survival challenge in lung cancer

    Imfinzi aces survival challenge in lung cancer. Earlier treatment leads to much extended lives, data suggests. ... second-line head and neck cancer, small cell lung cancer (SCLC) and bladder cancer.

  • J&J files ‘breakthrough’ bladder cancer drug in US J&J files ‘breakthrough’ bladder cancer drug in US

    J&J files ‘ breakthrough’ bladder cancer drug in US. Needed as most patients don't respond to checkpoint inhibitors. ... Johnson &Johnson has filed for approval of a new targeted bladder cancer therapy in the US, setting up a possible approval next

  • Vyriad inks immunotherapy alliance with Merck/Pfizer Vyriad inks immunotherapy alliance with Merck/Pfizer

    The drug – sold as Bavencio – has been approved for skin cancer Merkel cell carcinoma and bladder cancer, but in February failed a trial as a second-line therapy for non-small ... cell lung cancer and also had a knockback in third-line stomach cancer

More from news
Approximately 21 fully matching, plus 103 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Cavatak is now in three trials in melanoma, bladder cancer and NSCLC that are due to generate results in 2018/2019.

  • Accelerating innovation Accelerating innovation

    Also on Ipsen’s radar are opportunities in pancreatic cancer, where it’s keen to maintain the momentum gained from Merrimack’s Onivyde. ... We try to [focus on] pancreas, liver and bladder cancer, where there are very few opportunities for patients

  • Deal Watch October 2015 Deal Watch October 2015

    Immunomic Therapeutics will retain the rights to its LAMP-vax platform for other applications, including cancer immunotherapy. ... MCNA for non-muscle invasive bladder cancer (BLA filed). Licence. 137. Proteros biostructures/ Merck &Co.

  • Interview: Trevor Smith, Takeda Interview: Trevor Smith, Takeda

    There's prostate cancer drug orteronel (TAK-700) and vedolizumab for Crohn's disease and ulcerative colitis, and then the atypical antipsychotic lurasidone. ... drug and the risk of bladder cancer.

  • Country report: The healthcare market in Japan Country report: The healthcare market in Japan

    The largest therapeutic category is Renin-angiotensin system agents (antihypertensive), followed by anti-neoplastics (cancer drugs). ... bladder cancer.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
An agency called Owen

We’re a Healthcare Communications Agency specialising in Multi-channel Marketing to make you Digitally Fitter, Stronger & Faster....

Latest intelligence

World Diabetes Day: Interaction and impact of diabetes on mental health
For World Diabetes Day on the 14th November 2018, Nisha Shahrukh - Medical Writer at Mednet Group has written an article depicting the impact diabetes has on mental health. Including...
EU
Innovation in merger control and the impact on the pharmaceutical sector
Is focusing on pipeline products enough to assess regulatory risks?...
Nudge-nudge, think-think
Chris Ross examines the personal complexities of human behaviour – and explains why fun, emotion and peer endorsement could be key to designing effective behavioural change programmes...

Infographics